{"disease":{"id":"her-2-gene-amplification","name":"her 2 gene amplification"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04650451","title":"Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":220,"lead_sponsor_name":"Bellicum Pharmaceuticals","has_results":false},{"nct_id":"NCT03979911","title":"Evaluation of Pertuzumab-Trastuzumab and Taxane in the Standard Treatment of Metastatic Breast Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":63,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT03602079","title":"Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Klus Pharma Inc.","has_results":false},{"nct_id":"NCT04660929","title":"CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Carisma Therapeutics Inc","has_results":false},{"nct_id":"NCT04215159","title":"Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":42,"lead_sponsor_name":"Jin-Hee Ahn","has_results":false},{"nct_id":"NCT05318339","title":"A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT05511844","title":"Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":25,"lead_sponsor_name":"Orum Therapeutics USA, Inc.","has_results":false},{"nct_id":"NCT03783936","title":"Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Ashwin Somasundaram","has_results":true},{"nct_id":"NCT03630809","title":"Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":16,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":false},{"nct_id":"NCT03613168","title":"Trastuzumab in HER2-positive Biliary Tract Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"Changhoon Yoo","has_results":false}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}